Indivior declares $8.13 per share special dividend tied to Supernus merger closing

Indivior Pharmaceuticals, Inc. announced on September 17, 2026 that its board of directors declared a special cash dividend of $8.13 per share of common stock, payable to holders of record as of October 30, 2026, with the same $8.13 per share amount applying to Indivior common stock underlying certain outstanding equity awards.¹ Those award holders would receive payment only once their awards vest.

The payout depends entirely on completion of Indivior's merger with Supernus Pharmaceuticals, Inc. The deal is expected to close on or about November 2, 2026, subject to approval by Indivior stockholders of the stock issuance tied to the merger, adoption of the merger agreement by Supernus stockholders, and satisfaction or waiver of other closing conditions under the merger agreement.¹ If the merger does not close, the special dividend will not be paid.

Assuming the merger closes on November 2, 2026, Indivior expects to pay the special dividend to eligible record holders on or about November 6, 2026.¹ Supernus stockholders will not receive the special dividend on any Indivior shares they receive as merger consideration.¹

On tax treatment, Indivior said it expects at least a majority of the special dividend to exceed its current and accumulated earnings and profits, though no assurance can be given, and such amounts would be treated by U.S. holders first as a return of capital up to the holder's stock basis, then as capital gain.¹ Further detail is referenced in the joint proxy statement/prospectus Indivior filed with the SEC on September 11, 2026.

The underlying transaction structure has Merger Sub, a wholly owned Indivior subsidiary, merging into Supernus, with Supernus continuing as the surviving company and a wholly owned subsidiary of Indivior following the transaction.¹